Florfenicol (Nuflor)

Florfenicol is a synthetic broad-spectrum antibiotic belonging to the amphenicol class of antimicrobial agents. It is a fluorinated derivative of thiamphenicol and is structurally related to chloramphenicol, though it lacks the nitro group associated with the serious bone marrow toxicity seen with chloramphenicol use in humans. Marketed under the brand name Nuflor among others, florfenicol has become an important antibiotic option in veterinary medicine for treating various bacterial infections. While primarily approved for use in cattle and swine, florfenicol is used off-label in dogs to treat susceptible bacterial infections when other first-line antibiotics have failed or when culture and sensitivity testing indicates its appropriateness.

Florfenicol exerts its antibacterial effects by binding to the 50S ribosomal subunit of bacteria, thereby inhibiting bacterial protein synthesis. This mechanism disrupts the ability of bacteria to produce essential proteins needed for growth and reproduction. The drug demonstrates bacteriostatic activity at lower concentrations, meaning it prevents bacterial multiplication, while at higher concentrations it can exhibit bactericidal properties against certain organisms. Florfenicol is effective against a wide range of gram-positive and gram-negative bacteria, including many strains that have developed resistance to other antibiotics through acetyltransferase production, as the fluorine substitution prevents this common resistance mechanism.

In veterinary practice, florfenicol is available primarily as an injectable solution, though oral formulations exist for certain species. The injectable form is typically administered via intramuscular or subcutaneous routes, while oral administration may be used in dogs when appropriate formulations are available or when the injectable solution is given orally. The drug is highly lipophilic, which allows it to achieve good tissue penetration and reach therapeutic concentrations in various body compartments, including the central nervous system where it can cross the blood-brain barrier. In dogs, the half-life of florfenicol is relatively short compared to other species, approximately one to two hours, which may necessitate more frequent dosing to maintain effective drug levels.

The safety profile of florfenicol in dogs is generally considered acceptable when used appropriately under veterinary supervision, though it is important to note that comprehensive safety studies specifically in canine patients are limited compared to approved species. Veterinary guidance is essential when considering florfenicol therapy in dogs, as proper dosing must account for the unique pharmacokinetic properties in this species. The drug should only be used when indicated based on culture and sensitivity results or when clinical judgment supports its use for specific infections. Completing the full prescribed course of treatment is crucial to prevent the development of bacterial resistance and ensure complete resolution of the infection.

Florfenicol is primarily indicated in dogs for the treatment of bacterial infections caused by susceptible organisms, particularly when other first-line antibiotics have proven ineffective or when culture and sensitivity testing specifically identifies florfenicol as an appropriate choice. The drug demonstrates activity against numerous gram-positive and gram-negative bacteria commonly encountered in veterinary practice, making it a valuable option for infections that have failed to respond to more conventional antimicrobial therapy. Its broad-spectrum coverage includes activity against Staphylococcus species, Streptococcus species, Pasteurella multocida, Mannheimia haemolytica, Escherichia coli, and various other pathogens implicated in canine bacterial diseases.

One of the most common applications of florfenicol in dogs is the treatment of bacterial skin infections, including pyoderma caused by Staphylococcus pseudintermedius and other cutaneous pathogens. The drug's excellent tissue penetration makes it particularly useful for deep pyoderma and skin infections that have not responded to conventional antibiotic therapy. Dermatological conditions of bacterial etiology, including chronic or recurrent skin infections, represent a significant portion of florfenicol's off-label use in companion animals. Additionally, florfenicol is frequently employed in the treatment of otitis externa, which is among the most common diagnoses in companion animal practice, particularly when the infection involves bacteria susceptible to this antibiotic.

Respiratory tract infections in dogs may also be treated with florfenicol when appropriate. The drug's ability to achieve therapeutic concentrations in respiratory tissues and its activity against common respiratory pathogens make it a consideration for pneumonia and other lower respiratory infections, particularly those caused by organisms resistant to more commonly used antibiotics. The high lipophilicity of florfenicol allows for excellent penetration into pulmonary tissues, enhancing its effectiveness against respiratory pathogens. Florfenicol may also be considered for upper respiratory infections when bacterial involvement is confirmed.

Recent veterinary research has explored the potential use of florfenicol for urinary tract infections in dogs. Studies examining urinary excretion of florfenicol suggest that the drug may achieve adequate concentrations in urine to treat susceptible uropathogens, though more research is needed to establish optimal dosing protocols for this indication. The drug may be considered for complicated or resistant urinary tract infections when other options have been exhausted. Florfenicol has also been used to treat various other bacterial infections including soft tissue infections, wound infections, and in some cases, infections involving the central nervous system due to its ability to cross the blood-brain barrier.

Veterinarians may select florfenicol over other antibiotics in several clinical scenarios. The drug is particularly valuable when dealing with multidrug-resistant bacterial infections, as florfenicol often retains activity against organisms that have developed resistance to other antibiotic classes. Its unique mechanism of resistance prevention through fluorine substitution means that bacteria utilizing acetyltransferase-mediated resistance to chloramphenicol may still be susceptible to florfenicol. The decision to use florfenicol should always be based on culture and sensitivity results when possible, and the drug should be reserved for situations where its use is clearly indicated to preserve its effectiveness and minimize the development of resistance.

The dosing of florfenicol in dogs requires careful veterinary consideration, as the drug is used off-label in this species and optimal dosing protocols are still being refined through ongoing research. The veterinarian will determine the appropriate dose based on the individual patient's weight, the type and severity of infection being treated, and the route of administration chosen. Accurate body weight measurement is essential for calculating the correct dose, as both underdosing and overdosing can lead to treatment failure or increased risk of adverse effects. Dog owners should never attempt to dose florfenicol without explicit veterinary guidance, as inappropriate use could compromise treatment outcomes and contribute to antimicrobial resistance.

General dosing guidelines for florfenicol in dogs typically range from 20 to 40 mg per kilogram of body weight, though the exact dose and frequency will depend on the clinical situation and veterinary judgment. Some protocols call for administration once daily, while others may require twice-daily dosing due to the relatively short half-life of the drug in dogs compared to other species. The frequency of administration is particularly important with florfenicol, as maintaining adequate drug concentrations is essential for therapeutic efficacy. In dogs, the elimination half-life is approximately 1.1 to 1.2 hours after intravenous or oral administration, which is considerably shorter than in cattle or cats, potentially necessitating more frequent dosing intervals.

The duration of florfenicol treatment in dogs varies depending on the type of infection being treated and the clinical response observed. For skin infections and otitis externa, treatment courses typically range from one to several weeks, while more serious or deep-seated infections may require longer therapy. The veterinarian will assess the patient's response to treatment and determine when the course can be safely concluded. For dermatological conditions, treatment is often continued for at least one week beyond clinical resolution to ensure complete elimination of the pathogen. Follow-up evaluation is important to confirm treatment success and identify any need for extended therapy.

Florfenicol administration in dogs may be accomplished through injectable or oral routes, depending on the formulation available and the clinical circumstances. When using the injectable solution for intramuscular or subcutaneous administration, proper injection technique is important to minimize local tissue reactions. For oral administration, the injectable solution may be given by mouth, though owners should be aware that florfenicol has a bitter taste that some dogs find objectionable. Administering the medication with food may help with palatability and reduce gastrointestinal upset, though absorption characteristics should be discussed with the prescribing veterinarian. Some dogs may exhibit salivation or head shaking in response to the taste when given orally.

If a dose of florfenicol is missed, it should be given as soon as the owner remembers, unless it is close to the time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Owners should never give a double dose to make up for a missed one, as this increases the risk of adverse effects without providing therapeutic benefit. For preventive or prophylactic uses, maintaining a consistent dosing schedule is particularly important. If multiple doses are missed or if there are concerns about treatment compliance, the veterinarian should be contacted for guidance on how to proceed.

Completing the full course of florfenicol therapy as prescribed is essential for successful treatment outcomes. Stopping the antibiotic prematurely, even if the dog appears to have improved, can result in incomplete elimination of the bacteria and lead to relapse of the infection. More importantly, incomplete treatment courses contribute to the development of antibiotic resistance, which is an increasingly serious concern in both veterinary and human medicine. Owners should contact their veterinarian before discontinuing therapy if they have concerns about side effects or other issues, rather than stopping the medication independently. The veterinarian may adjust the treatment plan if necessary while ensuring appropriate antimicrobial stewardship.

Florfenicol is generally well-tolerated in dogs when administered at appropriate doses under veterinary supervision, though as with any medication, adverse effects can occur. The overall safety profile of florfenicol in dogs appears favorable based on available clinical experience and limited research, but comprehensive safety studies specifically in canine patients are not as extensive as those conducted in approved species such as cattle and swine. Dog owners should be aware of potential side effects and monitor their pets during treatment, reporting any concerning symptoms to their veterinarian promptly. Most adverse effects are mild and resolve with discontinuation of the medication or symptomatic treatment.

The most commonly observed side effects of florfenicol in dogs involve the gastrointestinal system. Dogs may experience decreased appetite, vomiting, diarrhea, or soft stools during treatment. These effects are typically mild to moderate in severity and often improve as the dog adjusts to the medication or with administration alongside food. Gastrointestinal upset may be more pronounced when the drug is given orally, particularly if administered on an empty stomach. The bitter taste of florfenicol can cause some dogs to salivate excessively or show aversion to taking the medication. If gastrointestinal symptoms are severe or persistent, the veterinarian should be consulted about possible dose adjustments or alternative treatment options.

Less common but noteworthy side effects may include changes in behavior or neurological signs. Some dogs may appear lethargic or less active during florfenicol treatment, though this could also reflect the underlying illness being treated. Given that florfenicol can cross the blood-brain barrier, any unusual neurological symptoms should be promptly reported to the veterinarian. Additionally, local tissue reactions may occur at injection sites when the drug is administered via intramuscular or subcutaneous routes, including swelling, pain, or inflammation at the injection location. These reactions are usually transient and resolve without specific treatment.

Serious adverse effects from florfenicol are uncommon but require immediate veterinary attention. Signs of a severe allergic reaction, such as facial swelling, hives, difficulty breathing, or collapse, should be treated as emergencies. Although florfenicol lacks the nitro group associated with chloramphenicol-induced aplastic anemia in humans, any signs of bone marrow suppression such as unusual bleeding, bruising, pale gums, or increased susceptibility to infections should prompt immediate veterinary evaluation. Hepatotoxicity, while not commonly reported, is a potential concern with prolonged therapy, and signs such as jaundice, severe vomiting, or changes in appetite could indicate liver involvement.

Rare side effects and long-term use considerations should be discussed with the veterinarian before initiating florfenicol therapy. While the drug has a relatively good safety record in veterinary use, prolonged or repeated courses may carry additional risks that should be weighed against the benefits of treatment. Monitoring blood work may be recommended for dogs receiving extended therapy to detect any subclinical organ effects. Owners should seek veterinary care if their dog shows any signs of illness during treatment, including persistent gastrointestinal upset, behavioral changes, injection site reactions that worsen or do not improve, signs of allergic reaction, or any other symptoms that concern them. Early recognition and reporting of adverse effects allows for prompt intervention and adjustment of the treatment plan as needed.

Florfenicol is contraindicated in dogs with known hypersensitivity or allergic reactions to the drug or to other amphenicol antibiotics, including thiamphenicol and chloramphenicol. Dogs that have previously experienced adverse reactions to any member of this antibiotic class should not receive florfenicol, as cross-reactivity between these related compounds is possible. Any history of allergic reactions to medications should be disclosed to the veterinarian before treatment begins, allowing for selection of an alternative antibiotic if necessary. Signs of previous hypersensitivity reactions may include skin rashes, facial swelling, respiratory distress, or anaphylactic responses.

Dogs with significant liver or kidney dysfunction may require special consideration before florfenicol therapy is initiated. While florfenicol undergoes hepatic metabolism and both the parent drug and metabolites are excreted through various routes including the kidneys, impaired organ function could affect drug clearance and increase the risk of toxicity. Veterinarians will evaluate liver and kidney function through blood work when appropriate before prescribing florfenicol, particularly in dogs with known hepatic or renal disease. Alternative antibiotics may be preferred in patients with compromised organ function to minimize the risk of adverse effects. Dose adjustments might be necessary in some cases if florfenicol is deemed the most appropriate treatment option despite organ impairment.

The safety of florfenicol in pregnant and lactating dogs has not been established, and the drug should generally be avoided in these populations unless the potential benefits clearly outweigh the risks to the developing puppies or nursing neonates. Reproductive safety studies have not been conducted specifically in dogs, and caution is warranted given the potential for any antibiotic to affect fetal development or nursing offspring. Breeding dogs of both sexes should also be treated with caution, as the effects of florfenicol on fertility and reproductive function in dogs are not fully characterized. Veterinarians will consider the reproductive status of the patient when making treatment decisions. Additionally, the use of florfenicol in very young puppies has not been extensively studied, and age-appropriate antibiotic selection may be preferred in neonatal and pediatric patients.

Other medical conditions may also preclude the use of florfenicol or require careful monitoring during treatment. Dogs with pre-existing bone marrow disorders or those receiving medications that affect bone marrow function should be treated with caution, as amphenicol antibiotics have the potential to affect hematopoiesis. Dogs that are severely debilitated, dehydrated, or immunocompromised may be at increased risk for adverse effects and require stabilization before antibiotic therapy or selection of alternative treatments. A complete medical history, including all current medications, supplements, and previous drug reactions, should be provided to the veterinarian before starting florfenicol. This comprehensive disclosure ensures that potential contraindications and drug interactions are identified and appropriate treatment decisions can be made for the individual patient.

Informing the veterinarian about all medications, supplements, and over-the-counter products the dog is receiving is essential before starting florfenicol therapy. Drug interactions can significantly affect the safety and efficacy of treatment, potentially leading to increased toxicity, reduced antibiotic effectiveness, or complications in managing other medical conditions. The veterinarian needs complete information to assess potential interactions and make appropriate adjustments to the treatment plan. Even seemingly innocuous supplements or occasional medications should be disclosed, as interactions can occur with unexpected combinations.

Florfenicol may interact with other antibiotics and antimicrobial agents. Concurrent use with chloramphenicol or thiamphenicol should be avoided due to the similar mechanisms of action and potential for additive toxicity without enhanced therapeutic benefit. The use of florfenicol alongside bactericidal antibiotics may potentially result in antagonistic effects, as the bacteriostatic action of amphenicol antibiotics could interfere with the killing mechanisms of bactericidal drugs that require actively dividing bacteria. However, this theoretical concern does not always translate to clinical significance, and combination therapy decisions should be made on a case-by-case basis by the veterinarian. Aminoglycoside antibiotics and florfenicol combinations should be used cautiously, with attention to potential nephrotoxicity.

Interactions between florfenicol and commonly used supplements or dietary factors in dogs should be considered. While specific studies on food-drug interactions with florfenicol in dogs are limited, general principles of antibiotic administration apply. The oral bioavailability of florfenicol may be affected by administration with or without food, and the veterinarian will provide guidance on optimal timing of doses relative to meals. Joint supplements containing glucosamine and chondroitin, omega-3 fatty acid supplements, and probiotics are commonly given to dogs and should be mentioned to the veterinarian, though significant interactions with florfenicol are not well documented. Timing the administration of probiotics separately from antibiotic doses may help preserve beneficial gut bacteria.

Monitoring and management strategies are important when florfenicol is used in conjunction with other treatments. If the dog is receiving medications that affect liver function or that are metabolized by hepatic enzymes, closer monitoring may be warranted. Similarly, drugs that affect kidney function could theoretically alter florfenicol elimination. The veterinarian may recommend periodic blood work to assess liver and kidney function during treatment, particularly if the dog is on multiple medications or has underlying health conditions. Signs of potential drug interactions to watch for include unexpected changes in the dog's condition, increased side effects from either florfenicol or other medications, or decreased effectiveness of any treatment. Any new symptoms or concerns during treatment should be reported to the veterinarian, who can evaluate whether a drug interaction might be contributing and adjust the treatment plan accordingly.

Standard precautions for the use of florfenicol in dogs include ensuring proper veterinary supervision throughout the treatment course, obtaining accurate body weight measurements for dose calculation, and following the prescribed dosing regimen exactly as directed. Dog owners should understand that florfenicol is used off-label in dogs, meaning it is not specifically approved for canine use but may be legally prescribed by veterinarians when medically appropriate. This off-label status underscores the importance of veterinary guidance, as dosing recommendations and safety monitoring may differ from approved species. Owners should not share florfenicol between pets or use remaining medication from previous treatments without veterinary consultation.

While breed-specific concerns with florfenicol are not as pronounced as with some other medications, certain genetic sensitivities should be considered. Dogs with the MDR1 (ABCB1) gene mutation, common in herding breeds such as Collies, Australian Shepherds, Shetland Sheepdogs, and related breeds, may have altered drug metabolism and increased sensitivity to various medications. Although florfenicol is not among the drugs most commonly associated with MDR1-related toxicity, the presence of this mutation should be disclosed to the veterinarian. Genetic testing for MDR1 status is available and may be recommended for at-risk breeds before initiating therapy with any medication. Mixed-breed dogs with herding breed ancestry may also carry the mutation and should be treated with appropriate caution.

Environmental precautions are important when handling florfenicol to protect both the pet and household members. The injectable solution should be handled with care to avoid accidental human exposure, particularly for individuals who may be allergic to amphenicol antibiotics or who are pregnant. Gloves may be recommended when administering injections or handling the medication. Florfenicol should be kept out of reach of children and other pets, as accidental ingestion could cause adverse effects. In multi-pet households, treated dogs should be monitored to ensure other animals do not have access to the medication. Any spills of the injectable solution should be cleaned promptly and safely.

Monitoring the dog during florfenicol treatment is essential for detecting both therapeutic response and potential adverse effects. Owners should observe for signs of improvement in the condition being treated, such as reduced infection symptoms, improved appetite, and increased energy. Conversely, any signs of adverse effects including gastrointestinal upset, lethargy, changes in appetite, injection site reactions, or neurological symptoms should prompt consultation with the veterinarian. For dogs receiving extended therapy, periodic veterinary examinations and blood work may be recommended to monitor organ function and overall health. Keeping a simple log of doses given and any observed effects can be helpful for veterinary follow-up appointments.

Special populations of dogs require additional consideration when florfenicol therapy is being contemplated. Geriatric dogs may have reduced liver or kidney function that affects drug metabolism and elimination, potentially increasing the risk of adverse effects or requiring dose adjustments. Puppies, particularly those under a few months of age, may have immature organ systems that handle medications differently than adult dogs. Immunocompromised dogs or those with serious underlying diseases may be more susceptible to adverse effects and require closer monitoring. Working dogs, performance dogs, and dogs in active training programs should be monitored for any effects on activity level or performance during treatment. The veterinarian will consider all individual patient factors when determining whether florfenicol is appropriate and what monitoring protocols should be implemented.

Proper storage of florfenicol is essential to maintain the medication's stability and effectiveness throughout the treatment course. The injectable solution should be stored at controlled room temperature, typically between 15 and 25 degrees Celsius (59 to 77 degrees Fahrenheit), protected from light and excessive heat. The medication should not be frozen, as this may affect its physical properties and stability. Storage in a cool, dry location away from direct sunlight, heat sources, and humidity is recommended. Florfenicol should not be stored in galvanized metal containers, as interaction with the metal may cause degradation of the product. Following the manufacturer's specific storage recommendations on the product label ensures optimal medication quality.

Different formulations of florfenicol may have specific storage requirements that should be followed carefully. The injectable solution, once the vial has been entered, should be used according to the timeframe specified on the product label, which is typically within a certain number of days to weeks depending on the formulation. Multi-dose vials should be handled aseptically to prevent contamination, using sterile technique when withdrawing doses. If an oral suspension is compounded or prepared, storage requirements for the reconstituted product may differ from the original solution, and pharmacist or veterinary guidance should be followed. Expiration dates on all medication containers should be checked before use, and expired medications should not be administered.

Safe handling of florfenicol protects both the dog and the humans administering the medication. The injectable formulation can be irritating to skin and eyes, so contact should be avoided. Washing hands thoroughly before and after handling the medication is recommended, and gloves may be appropriate for individuals with sensitive skin or those administering frequent doses. In case of accidental skin contact, the area should be washed with soap and water. If eye exposure occurs, flushing with water for at least fifteen minutes and seeking medical attention is advised. Pregnant women should exercise particular caution when handling florfenicol, as the effects of the drug on human fetal development are not fully established. Accidental human ingestion should prompt contact with a poison control center or medical professional.

Proper disposal of unused or expired florfenicol is important for environmental safety and to prevent accidental exposure. Unused medication should not be poured down drains or flushed down toilets, as this can contaminate water supplies and harm aquatic organisms. Many veterinary clinics and pharmacies participate in drug take-back programs that provide safe disposal options for unused medications. Local guidelines for medication disposal should be followed, and some communities have specific collection events for pharmaceutical waste. Empty vials and syringes used for administration should be disposed of safely in appropriate sharps containers when applicable. Keeping medications secured until disposal prevents access by children, pets, and wildlife.

The majority of dog breeds tolerate florfenicol therapy without significant breed-related concerns when the medication is used appropriately under veterinary supervision. However, certain genetic factors and breed characteristics may influence how individual dogs respond to the medication, making it important for veterinarians and owners to consider breed-specific factors when treatment decisions are made. Understanding these considerations helps ensure the safest and most effective use of florfenicol across the diverse range of canine patients.

The MDR1 (ABCB1) gene mutation represents the most significant genetic consideration for drug therapy in dogs, though florfenicol is not among the drugs most commonly implicated in MDR1-related toxicity. Breeds with high prevalence of this mutation include Collies (where up to 70 percent may be affected), Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, English Shepherds, Border Collies, Long-haired Whippets, Silken Windhounds, and mixed-breed dogs with herding breed ancestry. The MDR1 gene encodes a protein pump that helps remove certain drugs from the brain and other tissues; when this gene is mutated, affected dogs may experience increased drug levels in the brain and enhanced sensitivity to various medications. While florfenicol crosses the blood-brain barrier and could theoretically be affected by MDR1 status, specific interactions are not well documented. Genetic testing is available to determine MDR1 status and may be recommended before initiating therapy with any medication in at-risk breeds.

Size-related considerations are important for accurate florfenicol dosing across the wide range of dog sizes. Giant breeds such as Great Danes, Mastiffs, and Saint Bernards require larger total doses that must be carefully calculated based on accurate body weight. Very large dogs may need divided doses or multiple injection sites to avoid excessive volumes at any single location. Conversely, toy breeds such as Chihuahuas, Yorkshire Terriers, and Pomeranians require precise measurement of very small doses to avoid overdosing. The concentration of the injectable solution must be considered when calculating volumes for small patients, and compounded preparations at different concentrations may sometimes be needed. Accurate scales should be used to determine body weight, particularly for small dogs where even minor variations significantly affect the calculated dose.

Age-related considerations apply across all breeds and influence both dosing and monitoring during florfenicol therapy. Puppies have developing organ systems, including liver and kidneys that may not metabolize and eliminate drugs as efficiently as adult dogs. Young dogs may also have different body composition and fluid distribution that affects drug pharmacokinetics. The use of florfenicol in very young puppies should be carefully considered, and alternative antibiotics specifically studied in pediatric patients may be preferred when available. Senior dogs, typically those seven years and older (though this varies by breed with larger breeds aging faster), may have age-related decline in liver and kidney function that affects drug handling. Geriatric patients may require dose adjustments, extended dosing intervals, or additional monitoring during therapy. Baseline blood work to assess organ function is particularly valuable in older dogs before initiating antibiotic therapy.

Within the amphenicol antibiotic class, florfenicol has related compounds that share similar mechanisms of action but differ in their safety profiles and approved uses. Chloramphenicol is the original member of this antibiotic class, highly effective against many bacteria but limited in veterinary use due to concerns about human health risks from residues in food animals and the rare but serious risk of aplastic anemia in humans exposed to the drug. Thiamphenicol is another related compound that served as the direct structural predecessor to florfenicol. These drugs all work by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, but florfenicol's fluorine substitution provides resistance to common bacterial inactivation mechanisms that affect chloramphenicol and thiamphenicol.

For bacterial infections in dogs, numerous alternative antibiotic classes may be considered depending on the specific pathogen involved and susceptibility patterns. Beta-lactam antibiotics, including amoxicillin-clavulanate (Clavamox), cephalexin, and cefpodoxime, are commonly used first-line options for many canine bacterial infections. Fluoroquinolones such as enrofloxacin (Baytril) and marbofloxacin may be appropriate for certain infections, particularly those involving gram-negative bacteria or resistant organisms. Potentiated sulfonamides, tetracyclines including doxycycline, and macrolides represent additional antibiotic classes available for veterinary use. The selection of an alternative antibiotic should be guided by culture and sensitivity results when possible, as well as the location and nature of the infection.

Complementary therapies may support antibiotic treatment for bacterial infections in dogs. Probiotics may help maintain gastrointestinal health during antibiotic therapy by supporting beneficial gut bacteria. For skin infections, topical antimicrobial treatments including medicated shampoos, sprays, or ointments may be used alongside systemic antibiotics to enhance treatment effectiveness. Wound care, environmental management, and addressing underlying conditions that predispose to infection are important components of comprehensive treatment plans. Veterinary guidance is essential when considering any complementary therapy to ensure compatibility with florfenicol treatment and appropriate management of the underlying condition. Dog owners should never substitute one antibiotic for another or add complementary treatments without veterinary approval, as inappropriate combinations could reduce effectiveness or increase the risk of adverse effects.